About AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. (AVEO) is a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics. Its product candidates are directed against mechanisms known to be involved in cancer. The Companys product, Tivozanib, is a potent and selective oral inhibitor of the vascular endothelial growth factor (VEGF), – more... receptors 1, 2 and 3. It completed a 272-patient phase two clinical trial of tivozanib in patients with advanced renal cell cancer (RCC). In December 2009, the Company initiated a phase three clinical trial of tivozanib in patients with advanced RCC, in which it focuses to enroll 500 patients, referred to as the TIVO-1 study. The TIVO-1 study is a randomized, controlled clinical trial of tivozanib compared to Nexavar (sorafenib) in advanced RCC patients who have not received any prior VEGF-targeted therapy. Nexavar is an oral VEGF receptor inhibitor approved for the treatment of RCC. – less – More from ZoomInfo »
AVEO Pharmaceuticals, Inc. Jobs
AVEO Pharmaceuticals, Inc. Employer Reviews
Working at AVEO Pharmaceuticals, Inc.
